ArticleMedical mycology2026
Effect of postbiotics on biofilm formation and gene expression in Candida spp. isolates from patients with recurrent vulvovaginal candidiasis.
Article in Medical mycology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-line treatment for vulvovaginal candidiasis (VVC) has reduced efficacy in patients with recurrent VVC (RVVC), prompting the search for therapeutic alternatives such as probiotics. Recently, postbiotics (cellular components and metabolites derived from probiotics) have gained relevance because they offer similar benefits to probiotics without the risks associated with live microorganisms. This study aimed to evaluate the anti-biofilm effect of cell-free supernatants (CFSs) derived from probiotic strains against Candida spp. isolates from patients with RVVC, as well as their impact on the expression of genes associated with biofilm formation. Therefore, the anti-biofilm activity of CFSs from Lacticaseibacillus rhamnosus DM-UFMG 63, Bifidobacterium longum 5,1A and Lactobacillus acidophilus NCFM SD 5221 was evaluated in 40 Candida spp. isolates. The CFSs from L. acidophilus NCFM SD 5221 and Lc. rhamnosus 63 were analyzed using the XTT assay, and their effect on gene expression was measured by qPCR. At an estimated protein concentration of ∼200 μg/ml, these CFSs significantly inhibited biofilm formation by ∼ 50% (P < .01)). This phenotypic effect correlated with the downregulation of key biofilm-associated genes (ALS3, HWP1, EFG1, TEC1, and UME6), alongside a concomitant upregulation of the transcriptional repressor NRG1. The findings of this study demonstrate that CFSs derived from Lc. rhamnosus DM-UFMG 63 and L. acidophilus NCFM SD 5221 exhibit significant antagonistic activity against biofilm formation in clinical isolates from patients with RVVC. Consequently, these CFSs represent a promising therapeutic and prophylactic alternative for the management of RVVC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.